Selected research
Market Structure
Global Therapeutic Proteins and Oral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Therapeutic Proteins and Oral Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Therapeutic Proteins and Oral Vaccines include Abbott, Sanofi, Merck, Roche, Pfizer, Amgen, TransAlgae, Serum Institute of India and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Therapeutic Proteins and Oral Vaccines market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Therapeutic Proteins and Oral Vaccines and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Therapeutic Proteins and Oral Vaccines revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Therapeutic Proteins and Oral Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
Therapeutic Proteins and Oral Vaccines Segment by Company
Abbott
Sanofi
Merck
Roche
Pfizer
Amgen
TransAlgae
Serum Institute of India
Novo Nordisk
MigVax
Lumen Bioscience
Johnson and Johnson
Emergent Biosolutions
Eli Lilly and Company
Biogen
Therapeutic Proteins and Oral Vaccines Segment by Type
Therapeutic Proteins
Oral Vaccines
Therapeutic Proteins and Oral Vaccines Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Therapeutic Proteins and Oral Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins and Oral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins and Oral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins and Oral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Therapeutic Proteins and Oral Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Proteins and Oral Vaccines industry.
Chapter 3: Detailed analysis of Therapeutic Proteins and Oral Vaccines companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Proteins and Oral Vaccinesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Therapeutic Proteins
- Oral Vaccines
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Abbott
- Sanofi
- Merck
- Roche
- Pfizer
- Amgen
- TransAlgae
- Serum Institute of India
- Novo Nordisk
- MigVax
- Lumen Bioscience
- Johnson and Johnson
- Emergent Biosolutions
- Eli Lilly and Company
- Biogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Therapeutic Proteins
- 1.2.3 Oral Vaccines
- 1.3 Market Analysis by Application
- 1.3.1 Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Retail Pharmacies
- 1.3.3 Online Pharmacies
- 1.3.4 Hospital Pharmacies
- 1.4 Global Market Growth Prospects
- 1.5 Global Therapeutic Proteins and Oral Vaccines Growth Trends by Region
- 1.5.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Therapeutic Proteins and Oral Vaccines Market Size by Region (2021-2026)
- 1.5.3 Therapeutic Proteins and Oral Vaccines Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Therapeutic Proteins and Oral Vaccines Market Dynamics
- 2.1 Therapeutic Proteins and Oral Vaccines Industry Trends
- 2.2 Therapeutic Proteins and Oral Vaccines Industry Drivers
- 2.3 Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges
- 2.4 Therapeutic Proteins and Oral Vaccines Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Therapeutic Proteins and Oral Vaccines Revenue by Company (2021-2026)
- 3.2 Global Therapeutic Proteins and Oral Vaccines Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Therapeutic Proteins and Oral Vaccines Key Company Head office and Area Served
- 3.4 Global Therapeutic Proteins and Oral Vaccines Company, Product Type & Application
- 3.5 Global Therapeutic Proteins and Oral Vaccines Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Therapeutic Proteins and Oral Vaccines Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Therapeutic Proteins and Oral Vaccines Players Market Share by Revenue in 2025
- 3.6.3 2025 Therapeutic Proteins and Oral Vaccines Tier 1, Tier 2, and Tier 3
4 Therapeutic Proteins and Oral Vaccines Market by Type
- 4.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2032)
- 4.3 Global Therapeutic Proteins and Oral Vaccines Market Size Share by Type (2021-2032)
5 Therapeutic Proteins and Oral Vaccines Market by Application
- 5.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2032)
- 5.3 Global Therapeutic Proteins and Oral Vaccines Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Abbott
- 6.1.1 Abbott Company Information
- 6.1.2 Abbott Business Overview
- 6.1.3 Abbott Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.1.5 Abbott Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Merck
- 6.3.1 Merck Company Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Merck Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Roche Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Amgen
- 6.6.1 Amgen Company Information
- 6.6.2 Amgen Business Overview
- 6.6.3 Amgen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.6.5 Amgen Recent Developments
- 6.7 TransAlgae
- 6.7.1 TransAlgae Company Information
- 6.7.2 TransAlgae Business Overview
- 6.7.3 TransAlgae Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.7.5 TransAlgae Recent Developments
- 6.8 Serum Institute of India
- 6.8.1 Serum Institute of India Company Information
- 6.8.2 Serum Institute of India Business Overview
- 6.8.3 Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.8.5 Serum Institute of India Recent Developments
- 6.9 Novo Nordisk
- 6.9.1 Novo Nordisk Company Information
- 6.9.2 Novo Nordisk Business Overview
- 6.9.3 Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.9.5 Novo Nordisk Recent Developments
- 6.10 MigVax
- 6.10.1 MigVax Company Information
- 6.10.2 MigVax Business Overview
- 6.10.3 MigVax Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.10.5 MigVax Recent Developments
- 6.11 Lumen Bioscience
- 6.11.1 Lumen Bioscience Company Information
- 6.11.2 Lumen Bioscience Business Overview
- 6.11.3 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.11.5 Lumen Bioscience Recent Developments
- 6.12 Johnson and Johnson
- 6.12.1 Johnson and Johnson Company Information
- 6.12.2 Johnson and Johnson Business Overview
- 6.12.3 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.12.5 Johnson and Johnson Recent Developments
- 6.13 Emergent Biosolutions
- 6.13.1 Emergent Biosolutions Company Information
- 6.13.2 Emergent Biosolutions Business Overview
- 6.13.3 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.13.5 Emergent Biosolutions Recent Developments
- 6.14 Eli Lilly and Company
- 6.14.1 Eli Lilly and Company Company Information
- 6.14.2 Eli Lilly and Company Business Overview
- 6.14.3 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.14.5 Eli Lilly and Company Recent Developments
- 6.15 Biogen
- 6.15.1 Biogen Company Information
- 6.15.2 Biogen Business Overview
- 6.15.3 Biogen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio
- 6.15.5 Biogen Recent Developments
7 North America
- 7.1 North America Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 7.2 North America Therapeutic Proteins and Oral Vaccines Market Size by Type
- 7.2.1 North America Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2026)
- 7.2.2 North America Therapeutic Proteins and Oral Vaccines Market Size by Type (2027-2032)
- 7.2.3 North America Therapeutic Proteins and Oral Vaccines Market Share by Type (2021-2032)
- 7.3 North America Therapeutic Proteins and Oral Vaccines Market Size by Application
- 7.3.1 North America Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2026)
- 7.3.2 North America Therapeutic Proteins and Oral Vaccines Market Size by Application (2027-2032)
- 7.3.3 North America Therapeutic Proteins and Oral Vaccines Market Share by Application (2021-2032)
- 7.4 North America Therapeutic Proteins and Oral Vaccines Market Size by Country
- 7.4.1 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 7.4.3 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 7.4.4 North America Therapeutic Proteins and Oral Vaccines Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 8.2 Europe Therapeutic Proteins and Oral Vaccines Market Size by Type
- 8.2.1 Europe Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2026)
- 8.2.2 Europe Therapeutic Proteins and Oral Vaccines Market Size by Type (2027-2032)
- 8.2.3 Europe Therapeutic Proteins and Oral Vaccines Market Share by Type (2021-2032)
- 8.3 Europe Therapeutic Proteins and Oral Vaccines Market Size by Application
- 8.3.1 Europe Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2026)
- 8.3.2 Europe Therapeutic Proteins and Oral Vaccines Market Size by Application (2027-2032)
- 8.3.3 Europe Therapeutic Proteins and Oral Vaccines Market Share by Application (2021-2032)
- 8.4 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country
- 8.4.1 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 8.4.3 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 8.4.4 Europe Therapeutic Proteins and Oral Vaccines Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 9.2 China Therapeutic Proteins and Oral Vaccines Market Size by Type
- 9.2.1 China Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2026)
- 9.2.2 China Therapeutic Proteins and Oral Vaccines Market Size by Type (2027-2032)
- 9.2.3 China Therapeutic Proteins and Oral Vaccines Market Share by Type (2021-2032)
- 9.3 China Therapeutic Proteins and Oral Vaccines Market Size by Application
- 9.3.1 China Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2026)
- 9.3.2 China Therapeutic Proteins and Oral Vaccines Market Size by Application (2027-2032)
- 9.3.3 China Therapeutic Proteins and Oral Vaccines Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 10.2 Asia Therapeutic Proteins and Oral Vaccines Market Size by Type
- 10.2.1 Asia Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2026)
- 10.2.2 Asia Therapeutic Proteins and Oral Vaccines Market Size by Type (2027-2032)
- 10.2.3 Asia Therapeutic Proteins and Oral Vaccines Market Share by Type (2021-2032)
- 10.3 Asia Therapeutic Proteins and Oral Vaccines Market Size by Application
- 10.3.1 Asia Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2026)
- 10.3.2 Asia Therapeutic Proteins and Oral Vaccines Market Size by Application (2027-2032)
- 10.3.3 Asia Therapeutic Proteins and Oral Vaccines Market Share by Application (2021-2032)
- 10.4 Asia Therapeutic Proteins and Oral Vaccines Market Size by Country
- 10.4.1 Asia Therapeutic Proteins and Oral Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 10.4.3 Asia Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 10.4.4 Asia Therapeutic Proteins and Oral Vaccines Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Type
- 11.2.1 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Application
- 11.3.1 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country
- 11.4.1 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst